Replies to post #185984 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Had to happen!

[jimmy667]

Anavex called Biogen bluff and handed them their hats and showed them the door yesterday with the Alliance between Anaxex, Sage and Cognition small innovative Companies with their new powerful Triad of CNS BPs Merck, Takeda and Lundbeck. Biogen and Eisia stuck in a rut were not invited to the ERP new CNS precision medicine Alliance.
Biogen damage control. Their goes BIIB aspirations to be a CNS leader. They snubbed Anavex and struck out.
Our CNS triad will crush Biogen in MS as well if the new trial methods pioneered by Anavex work out.

[FitzyP33]

Biogen down $75 to $245 per share.

[raja48185]

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease.

All the false assurances when they got together, when the results were no good last time, even as experts openly questioned the intent as Biogen tweaked and twisted the way the trial would be done.!! They are fooling no one.


The vote for Blank Preferred Check offered by AVXL becomes even more important in this context.

[attilathehunt]

I guess Biogen is not looking at us. If they were going to make an acquisition one would think they would do it while their share price was higher. They had to know that backing out of aducanumab would drop their share price significantly. Analyst had pegged appx 25% of their revenue from their Alzheimer’s drug. It look like we are the only game in town and hopefully draw attention to us. We should be approaching $20/sh before we hear any of readouts.